Survival or safety: Balancing act with Colistin

Journal of Global Infectious Diseases

Volumn 7, Issue 1, 2015, Pages 3-4

  Patil, Saiprasad ^a   Zirpe, Kapil ^b   Mukherjee, Dipnarayan ^c   Hajare, Anoop ^a   Korukonda, Krishnaprasad ^a   Bhargava, Amit ^a  

^a Glenmark Pharmaceuticals Limited   (India)

^b Neurointensive Care Ruby Hall Clinic   (India)

^c Woodlands Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN;

ACUTE KIDNEY FAILURE; AGE; CREATININE CLEARANCE; CRITICAL ILLNESS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG SAFETY; EDITORIAL; HEMODYNAMICS; HUMAN; MAINTENANCE DRUG DOSE; NONHUMAN; RACE DIFFERENCE; RISK ASSESSMENT; STEADY STATE;

EID: 84923083222     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.150881     Document Type: Editorial

References (13)

1. Ortwine JK, Kaye KS, Li J, Pogue JM. Colistin: Understanding and applying recent pharmacokinetic advances. Pharmacotherapy 2014 [In Press].
2. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21
3. Daikos GL, Skiada A, Pavleas J, Vafi adi C, Salatas K, Tofas P, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010;22:175-8
4. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85
5. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: Studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008;61:636-42
6. Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiol 2013;79:200-8
7. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51
8. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012;120:179-84
9. Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med 2014;18:427-30
10. Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, et al. Subacute toxicity of colistin methanesulfonate in rats: Comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 2008;52:1159-61
11. Dalfi no L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720-6
12. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008;14:816-27
13. Michalopoulos AS, Karatza DC, Gregorakos L. Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol 2011;7:245-55